Headlands Technologies LLC Invests $5.09 Million in Royalty Pharma PLC $RPRX

Headlands Technologies LLC acquired a new stake in shares of Royalty Pharma PLC (NASDAQ:RPRX) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 90,729 shares of the biopharmaceutical company’s stock, valued at approximately $5,087,000.

A number of other large investors have also added to or reduced their stakes in RPRX. Phillips Wealth Planners LLC increased its stake in Royalty Pharma by 1.9% during the 4th quarter. Phillips Wealth Planners LLC now owns 13,113 shares of the biopharmaceutical company’s stock valued at $521,000 after purchasing an additional 242 shares in the last quarter. Strs Ohio grew its holdings in shares of Royalty Pharma by 2.8% during the fourth quarter. Strs Ohio now owns 9,318 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 252 shares during the last quarter. Glenmede Trust Co. NA increased its position in shares of Royalty Pharma by 3.4% during the first quarter. Glenmede Trust Co. NA now owns 7,812 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 254 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its holdings in Royalty Pharma by 0.6% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,287 shares of the biopharmaceutical company’s stock worth $1,673,000 after acquiring an additional 255 shares during the last quarter. Finally, Cary Street Partners Financial LLC lifted its position in Royalty Pharma by 1.1% in the 4th quarter. Cary Street Partners Financial LLC now owns 24,405 shares of the biopharmaceutical company’s stock valued at $943,000 after acquiring an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Insider Buying and Selling

In other Royalty Pharma news, EVP Christopher Hite sold 150,000 shares of Royalty Pharma stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the transaction, the executive vice president owned 559,399 shares of the company’s stock, valued at $30,431,305.60. The trade was a 21.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 9,099 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $55.88, for a total transaction of $508,452.12. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 398,197 shares of company stock valued at $22,513,280. 18.84% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have issued reports on RPRX. Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Weiss Ratings restated a “buy (b-)” rating on shares of Royalty Pharma in a research report on Wednesday, August 12th. Bank of America reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Wednesday, August 5th. TD Cowen raised their price target on Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $65.00 price objective on shares of Royalty Pharma in a research report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Royalty Pharma presently has a consensus rating of “Buy” and a consensus price target of $60.86.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock opened at $60.85 on Monday. The stock has a market cap of $34.99 billion, a P/E ratio of 41.97, a P/E/G ratio of 1.42 and a beta of 0.43. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.80 and a current ratio of 2.80. The stock’s fifty day moving average is $58.16 and its 200 day moving average is $52.50. Royalty Pharma PLC has a one year low of $34.08 and a one year high of $62.46.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.05. The business had revenue of $674.14 million during the quarter, compared to analyst estimates of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. Sell-side analysts anticipate that Royalty Pharma PLC will post 5.3 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $0.235 per share. The ex-dividend date is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.5%. Royalty Pharma’s payout ratio is 64.83%.

Royalty Pharma Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.